Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,746.00
Bid: 4,732.00
Ask: 4,736.00
Change: 70.00 (1.50%)
Spread: 4.00 (0.085%)
Open: 4,676.00
High: 4,857.00
Low: 4,666.00
Prev. Close: 4,676.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic review of PT&IC businesses

5 May 2021 07:00

RNS Number : 5331X
Croda International PLC
05 May 2021
 

Press Release

5 May 2021

 

Strategic review of Performance Technologies & Industrial Chemicals businesses

Croda International Plc ("Croda" or the "Group"), which uses smart science to create high performance ingredients and technologies that improve lives, announces a strategic review of its Performance Technologies and Industrial Chemicals ('PTIC') businesses. The core objective will be to establish what ownership structure best serves this part of Croda's business going forward, to create a stronger platform for its future growth. The review is consistent with Croda's prioritisation of investments in faster-growth life science and consumer markets, which now represent over 80% of the Group's profitability.

PTIC is an excellent, world-leading business, with an impressive financial track record. It delivers industry-leading margins across the cycle through well invested manufacturing, innovation and sales operations, supported by a dedicated and experienced global team. It has a highly attractive portfolio, offering customers innovative, sustainable solutions in advanced technologies, and is focused on fast-growth markets in the circular plastic economy, electric vehicles and other renewable technologies. This strong technology portfolio supports PTIC's leading market positions in automotive, polymer and food packaging applications.

The scope of the strategic review will focus on the businesses and activities within PTIC that do not directly support the Consumer Care and Life Sciences sectors. It will consider whether Croda is the best future owner of all the PTIC businesses within the context of opportunities to deploy more capital and resources within PTIC, as well as in Consumer Care and Life Sciences.

The review will assess whether the full potential of PTIC can best be delivered under Croda, as a stand-alone business, or via a full or partial divestment. It will consider the extent of the mutual dependencies between PTIC and the rest of Croda, the practicality of all options, whilst prioritising the best interests of all stakeholders, including employees, customers and shareholders.

The review is expected to conclude by the end of 2021 and, in the meantime, the Group will continue to deliver an excellent service for its customers.

The strategic review is being launched in the context of ongoing improvement in Group trading year to date, continuing the trend seen in the second half of 2020. Customer demand is strong across all regions and sectors, including PTIC, in some cases driven by a recovery in end-consumer demand, in other areas by customer inventory build ahead of anticipated economic recovery. The Group will announce its Half Year Results to 30 June on 27 July 2021.

Further information

 

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Press: Charlie Armitstead, Teneo +44 7703 330269

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDQZLFBFELEBBQ
Date   Source Headline
27th Nov 20195:13 pmRNSHolding(s) in Company
25th Nov 20193:47 pmRNSHolding(s) in Company
22nd Nov 201910:17 amRNSDirector/PDMR Shareholding
12th Nov 20195:41 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
7th Nov 20196:04 pmRNSHolding(s) in Company
7th Nov 201910:04 amRNSHolding(s) in Company
1st Nov 20194:45 pmRNSDirector/PDMR Shareholding
15th Oct 20194:54 pmRNSTransaction in Own Shares
11th Oct 20195:40 pmRNSDirector/PDMR Shareholding
7th Oct 20197:00 amRNSCroda investor seminar focusing on Life Sciences
3rd Oct 20194:20 pmRNSDirector/PDMR Shareholding
13th Sep 20192:27 pmRNSDirector/PDMR Shareholding
11th Sep 20193:00 pmRNSDirector/PDMR Shareholding
11th Sep 20192:28 pmRNSHolding(s) in Company
13th Aug 20194:12 pmRNSDirector/PDMR Shareholding
25th Jul 20193:35 pmRNSDirector/PDMR Shareholding
24th Jul 20197:00 amRNSResults for the six months ended 30 June 2019
11th Jul 20193:11 pmRNSDirector/PDMR Shareholding
14th Jun 20193:01 pmRNSDirector/PDMR Shareholding
4th Jun 20193:24 pmRNSDirector/PDMR Shareholding
13th May 20193:20 pmRNSDirector/PDMR Shareholding
3rd May 20192:59 pmRNSDirector/PDMR Shareholding
1st May 20194:32 pmRNSDirector/PDMR Shareholding
29th Apr 20198:54 amRNSTotal Voting Rights
26th Apr 20198:21 amRNSTotal Voting Rights
25th Apr 201910:25 amRNSDirectorate Change
25th Apr 20199:53 amRNSResult of AGM
12th Apr 20194:28 pmRNSDirector/PDMR Shareholding
8th Apr 20194:45 pmRNSDirector/PDMR Shareholding
4th Apr 20199:32 amRNSDirector/PDMR Shareholding
2nd Apr 20199:04 amRNSDirector/PDMR Shareholding
28th Mar 201911:13 amRNSDirector/PDMR Shareholding
26th Mar 20198:16 amRNSDirector/PDMR Shareholding
18th Mar 20195:26 pmRNSAnnual Financial Report
13th Mar 20191:42 pmRNSDirector/PDMR Shareholding
12th Mar 20192:22 pmRNSDirector/PDMR Shareholding
12th Mar 20192:21 pmRNSDirector/PDMR Shareholding
11th Mar 20192:16 pmRNSDirector/PDMR Shareholding
6th Mar 20193:53 pmRNSTransaction in Own Shares
6th Mar 201910:07 amRNSDirector/PDMR Shareholding
6th Mar 201910:07 amRNSDirector/PDMR Shareholding
6th Mar 201910:06 amRNSDirector/PDMR Shareholding
6th Mar 201910:03 amRNSDirector/PDMR Shareholding
6th Mar 201910:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.